COST EFFECTIVENESS ANALYSIS OF BOCEPREVIR (BOC) ADDED TO PEGIFN/RIBAVIRIN (P/R) VERSUS PEGIFN/RIBAVIRIN (CURRENT STANDARD OF CARE) FOR THE TREATMENT OF PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C IN GREECE

Abstract

Abstract is not available.

    Similar works